

**Performa : Hindu College of Pharmacy**

**Lesson Plan**

<b>Name of the faculty</b>	<b>Swati saini</b>
<b>Discipline</b>	<b>Pharmacy</b>
<b>Year</b>	<b>2<sup>nd</sup> Year</b>
<b>Subject</b>	<b>Pharmacotherapeutics</b>
<b>Lesson plan Duration</b>	<b>25 weeks (Aug. 20, 2024 to April 30, 2025)</b>
<b>Work Load/week(In hour)</b>	<b>Lecture- 03; Practical- 03</b>

<b>Week</b>	<b>Theory</b>		<b>Practical</b>	
	<b>Lecture Day</b>	<b>Topic</b>	<b>Practical Day</b>	<b>Topic</b>
<b>1<sup>st</sup> (Aug 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Pharmacotherapeutics – Introduction, scope, and objectives	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Hypertension
	<b>2<sup>nd</sup></b>	Rational use of Medicines	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Evidence Based Medicine	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>2<sup>nd</sup> (Aug 5<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Essential Medicines List	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Angina Pectoris.
	<b>2<sup>nd</sup></b>	Standard Treatment Guidelines (STGs)	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Revision	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>3<sup>rd</sup>(Sep 2<sup>nd</sup> week)</b>	<b>1<sup>st</sup></b>	Cardiovascular System – Hypertension- Definition, Etiopathogenesis	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Myocardial infraction
	<b>2<sup>nd</sup></b>	Hypertension- Clinical manifestations, Management of the Diseases	<b>2<sup>nd</sup> (Batch B)</b>	----do----

	<b>3<sup>rd</sup></b>	Angina and Myocardial infarction- Definition, Etiopathogenesis	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>4<sup>th</sup>(Sep 3<sup>rd</sup> week)</b>	<b>1<sup>st</sup></b>	Angina and Myocardial infarction- Clinical manifestations, Management of the Diseases	<b>1<sup>st</sup> (Batch A)</b>	Viva voca
	<b>2<sup>nd</sup></b>	Hyperlipidaemia- Definition, Etiopathogenesis	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Hyperlipidaemia- Clinical manifestations, Management of the Diseases	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>5<sup>th</sup>(Sep 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Congestive Heart Failure- Definition, Etiopathogenesis	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Hyperlipidemia
	<b>2<sup>nd</sup></b>	Congestive Heart Failure- Clinical manifestations, Management of the Diseases	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Revision	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>6<sup>th</sup>(Oct 3<sup>rd</sup> week)</b>	<b>1<sup>st</sup></b>	Respiratory System- Asthma- Definition, Etiopathogenesis	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Rheumatoid Arthritis
	<b>2<sup>nd</sup></b>	Asthma- Clinical manifestations, Management of the Diseases	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	COPD- Definition, Etiopathogenesis	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>7<sup>th</sup>(Oct 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	COPD- Clinical manifestations, Management of the diseases	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Asthma
	<b>2<sup>nd</sup></b>	Endocrine System Diabetes- Definition, Etiopathogenesis	<b>2<sup>nd</sup> (Batch B)</b>	----do----

	<b>3<sup>rd</sup></b>	Diabetes- Clinical manifestations, Management of the Diseases	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>8<sup>th</sup> 9(Oct 5<sup>th</sup> and Nov 1<sup>st</sup> week)</b>	<b>1<sup>st</sup></b>	Hypothyroidism- Definition, Etiopathogenesis, Clinical manifestations, Management of the Diseases	<b>1<sup>st</sup> (Batch A)</b>	Viva Voca
	<b>2<sup>nd</sup></b>	Hyperthyroidism- Definition, Etiopathogenesis, Clinical manifestations, Management of the Diseases	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Revision	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>9<sup>th</sup>(Nov 2<sup>nd</sup> week)</b>	<b>1<sup>st</sup></b>	Central Nervous System- Epilepsy- Definition, Etiopathogenesis	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on COPD
	<b>2<sup>nd</sup></b>	Epilepsy-, Clinical manifestations, Management of the Diseases	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Parkinson's disease- Definition, Etiopathogenesis	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>10<sup>th</sup>(Nov.3<sup>rd</sup> week)</b>	<b>1<sup>st</sup></b>	Parkinson's disease-, Clinical manifestations, Management of the Diseases	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Diabetes
	<b>2<sup>nd</sup></b>	Alzheimer's disease- Definition, Etiopathogenesis, Clinical manifestations, Management of the Diseases	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Stroke- Definition, Etiopathogenesis, Clinical manifestations, Management of the Diseases	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>11<sup>th</sup>(Nov 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Migraine- Definition, Etiopathogenesis, Clinical manifestations, Management of the Diseases	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Epilepsy
	<b>2<sup>nd</sup></b>	Revision	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Gastro oesophageal reflux disease- Definition, Etiopathogenesis	<b>3<sup>rd</sup> (Batch C)</b>	----do----

<b>12<sup>th</sup>(Nov 5<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Gastro oesophageal reflux disease- Clinical manifestations, Management of the Diseases	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Stroke
	<b>2<sup>nd</sup></b>	Peptic Ulcer Disease- Definition, Etiopathogenesis	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Peptic Ulcer Disease- Clinical manifestations, Management of the Diseases	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>13<sup>th</sup>(Dec 1<sup>st</sup> week)</b>	<b>1<sup>st</sup></b>	Alcoholic liver disease- Definition, Etiopathogenesis	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Depression
	<b>2<sup>nd</sup></b>	Alcoholic liver disease- Clinical manifestations, Management of the Diseases	<b>3<sup>rd</sup> (Batch C)</b>	----do----
	<b>3<sup>rd</sup></b>	Inflammatory Bowel Diseases- Definition, Etiopathogenesis		----do----
<b>14<sup>th</sup>(Dec 2<sup>nd</sup> week)</b>	<b>1<sup>st</sup></b>	Inflammatory Bowel Diseases- Clinical manifestations, Management of the Diseases	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Tuberculosis
	<b>2<sup>nd</sup></b>	Revision	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Iron deficiency anaemia- Etiopathogenesis	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>15<sup>th</sup>(Dec 3<sup>rd</sup> week)</b>	<b>1<sup>st</sup></b>	Iron deficiency anaemia- Clinical manifestations, Management	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Anemia
	<b>2<sup>nd</sup></b>	Iron deficiency anaemia- Etiopathogenesis	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Iron deficiency anaemia- Clinical manifestations, Management	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>16<sup>th</sup> (Dec 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Tuberculosis	<b>1<sup>st</sup> (Batch A)</b>	Viva voce
	<b>2<sup>nd</sup></b>	Pneumonia	<b>2<sup>nd</sup> (Batch B)</b>	----do----

	<b>3<sup>rd</sup></b>	Urinary tract infections	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>17<sup>th</sup>(Jan.3<sup>rd</sup> week)</b>	<b>1<sup>st</sup></b>	Hepatitis	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Conjunctivitis viral infection
	<b>2<sup>nd</sup></b>	Gonorrhoea and Syphilis	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Malaria	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>18<sup>th</sup>(Jan 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Malaria	<b>1<sup>st</sup> (Batch A)</b>	To study the Preparation and discussion of SOAP on Psoriasis
	<b>2<sup>nd</sup></b>	HIV and Opportunistic infections	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Viral Infections (SARS, CoV2)	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>19<sup>th</sup>(Jan 5<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Revision	<b>1<sup>st</sup> (Batch A)</b>	Viva voce
	<b>2<sup>nd</sup></b>	Rheumatoid arthritis	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Osteoarthritis	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>20<sup>th</sup>(Feb 3<sup>rd</sup> week)</b>	<b>1<sup>st</sup></b>	Osteoarthritis- Definition, Etiopathogenesis, Clinical manifestations, Management	<b>1<sup>st</sup> (Batch A)</b>	To perform the study of medication condition, life style modification, monitoring parameters and maintaining documentation of patient counselling on Rheumatoid Arthritis
	<b>2<sup>nd</sup></b>	Psoriasis- Definition, Etiopathogenesis, Clinical manifestations, Management	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Scabies- Definition, Etiopathogenesis, Clinical manifestations, Management	<b>3<sup>rd</sup> (Batch C)</b>	----do----

21 <sup>st</sup> (Feb 4 <sup>th</sup> week)	1 <sup>st</sup>	Eczema- Definition, Etiopathogenesis, Clinical manifestations, Management	1 <sup>st</sup> (Batch A)	To perform the study of medication condition, life style modification, monitoring parameters and maintaining documentation of patient counselling on Hypertension
	2 <sup>nd</sup>	Psychiatric Disorders- Depression, Definition, Etiopathogenesis, Clinical manifestations, Management	2 <sup>nd</sup> (Batch B)	----do----
	3 <sup>rd</sup>	Anxiety- Definition, Etiopathogenesis, Clinical manifestations, Management	3 <sup>rd</sup> (Batch C)	----do----
22 <sup>nd</sup> (Feb 5 <sup>th</sup> week)	1 <sup>st</sup>	Psychosis- Definition, Etiopathogenesis, Clinical manifestations, Management	1 <sup>st</sup> (Batch A)	To perform the study of medication condition, life style modification, monitoring parameters and maintaining documentation of patient counselling on Asthma
	2 <sup>nd</sup>	Psychosis- Definition, Etiopathogenesis, Clinical manifestations, Management	2 <sup>nd</sup> (Batch B)	----do----
	3 <sup>rd</sup>	Revision	3 <sup>rd</sup> (Batch C)	----do----
23 <sup>rd</sup> (Mar 2 <sup>nd</sup> week)	1 <sup>st</sup>	Conjunctivitis (bacterial and )- Definition, Etiopathogenesis, Clinical manifestations, Management	1 <sup>st</sup> (Batch A)	To perform the study of medication condition, life style modification, monitoring parameters and maintaining documentation of patient counselling on Stroke
	2 <sup>nd</sup>	Revision	2 <sup>nd</sup> (Batch B)	----do----
	3 <sup>rd</sup>	Conjunctivitis ( viral)- Definition, Etiopathogenesis,	3 <sup>rd</sup> (Batch C)	----do----

<b>24<sup>th</sup>(Mar 3<sup>rd</sup> week)</b>	<b>1<sup>st</sup></b>	Conjunctivitis ( viral)- Clinical manifestations, Management	<b>1<sup>st</sup> (Batch A)</b>	To perform the study of medication condition, life style modification, monitoring parameters and maintaining documentation of patient counselling on Tuberculosis
	<b>2<sup>nd</sup></b>	Glaucoma- Definition, Etiopathogenesis,	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Glaucoma-Clinical manifestations, Management	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>25<sup>th</sup> (Mar 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Anti-microbial Resistance	<b>1<sup>st</sup> (Batch A)</b>	Viva voice
	<b>2<sup>nd</sup></b>	Anti-microbial Resistance	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Polycystic Ovary Syndrome- Definition.	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>26<sup>th</sup> (Mar 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Polycystic Ovary Syndrome- Etiopathogenesis, Clinical manifestations,	<b>1<sup>st</sup> (Batch A)</b>	To performed the dose calculation for the paediatrics and geriatric patient.
	<b>2<sup>nd</sup></b>	Polycystic Ovary Syndrome- Management	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Revision	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>27<sup>th</sup> (Mar 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Definition,	<b>1<sup>st</sup> (Batch A)</b>	Viva voice
	<b>2<sup>nd</sup></b>	Dysmenorrhoe- Etiopathogenesis, Clinical manifestations,	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Dysmenorrhoe- Management	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>28<sup>th</sup> (Mar 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Premenstrual Syndrome- Definition	<b>1<sup>st</sup> (Batch A)</b>	To performed the dose calculation for the paediatrics and geriatric patient.
	<b>2<sup>nd</sup></b>	Revision	<b>2<sup>nd</sup> (Batch B)</b>	----do----

	<b>3<sup>rd</sup></b>	Premenstrual Syndrome- Etiopathogenesis	<b>3<sup>rd</sup> (Batch C)</b>	----do----
<b>29<sup>th</sup> (Mar 4<sup>th</sup> week)</b>	<b>1<sup>st</sup></b>	Premenstrual Syndrome Clinical manifestations	<b>1<sup>st</sup> (Batch A)</b>	Viva voice
	<b>2<sup>nd</sup></b>	Premenstrual Syndrome- Management	<b>2<sup>nd</sup> (Batch B)</b>	----do----
	<b>3<sup>rd</sup></b>	Revision	<b>3<sup>rd</sup> (Batch C)</b>	----do----